Short answer
ASP Isotopes Inc. (ASPI) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $5M (up 4.8% year over year) with net income of −$31M.
Q3 2026 key financials · XBRL
- Revenue
- $5M
- +4.8% YoY · +0.0% QoQ
- Net income
- −$31M
- −139.4% YoY · +9.2% QoQ
- Operating margin
- -790.7%
- Gross margin
- 15.5%
- EPS (diluted)
- −$0.22
- −120.0% YoY · +18.5% QoQ
Source: XBRL data from the ASP Isotopes Inc. (ASPI) Q3 2026 10-Q on SEC EDGAR. USD.
ASP Isotopes Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $5.1M, up $3.9M YoY from $1.3M, led by radiopharmacy revenue of $4.3M
- Radiopharmacy gross margin 38% vs 19% YoY; Helium and LNG worst, negative gross margin 96%
- Specialist isotopes best segment, revenue $4.257M vs $1.271M; nuclear fuels revenue $0
- Cash $201.7M; operating cash flow use $66.4M for nine months vs $19.9M YoY
- Si-28 shipments targeted Q4 2026; Helium and LNG margins expected to improve in 2027, Phase 2 estimated above $1.0B
Risk Factors
- Merger risk newly added, triggered by ENDRA’s October 2, 2026 Form S-4 registration statement
- Renergen business risks incorporated by reference through Registration Statement Exhibit 99.1
- No material changes to 2025 Form 10-K risk factors beyond merger-related disclosures
- Merger execution risk, amendments or supplements to the S-4 may add material transaction information
- Carried-forward risks remain applicable, including risks disclosed in the amended 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ASP Isotopes Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.